Janux Therapeutics Inc (JANX NASDAQ) stock market data APIs
$29.0898
-1.24(-4.3%)
as of November 18, 2025
Try our APIs with
free plan!
Janux Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Prev. Close
29.0898
Open
27.8522
High
29.5241
Low
27.5103
52 wk Range
21.73-71.71
Market Cap
1 727 M
Shares Outstanding
60 148 K
Revenue
10 000 K
EPS
-0.39
Beta
2.824
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Janux Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Janux Therapeutics Inc data using free add-ons & libraries
Get Janux Therapeutics Inc Fundamental Data
Janux Therapeutics Inc Fundamental data includes:
- Net Revenue: 10 000 K
- EBITDA: -142 215 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.6173
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Janux Therapeutics Inc News
New
Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best small-cap biotech stocks to buy according to analysts.Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments i...
Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses
Janux Therapeutics reported its third-quarter 2025 results, posting a net loss of US$24.31 million, an improvement from US$28.06 million a year earlier, while its nine-month net loss grew year-over-ye...
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.51 per share a year ago. These fi...
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 $989.0 million in cash, cash equivalents, and short-term investments at end of third qu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
